Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Foris, V; Kovacs, G; Olschewski, H.
Pulmonale Hypertonie
Der Pneumologe. 2017; 14(2): 117-128. Doi: 10.1007/s10405-017-0097-y [OPEN ACCESS]
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Foris Vasile
Co-authors Med Uni Graz: Kovacs Gabor; Olschewski Horst
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: According to the current European Respiratory Society (ERS) and European Society of Cardiology (ESC) classification, pulmonary hypertension is subdivided into five groups. According to the guidelines a differentiation is made between pulmonary arterial hypertension (PAH, group 1), PH due to left heart diseases (group 2), PH due to lung diseases and/or hypoxemia (group 3), chronic thromboembolic PH (CTEPH, group 4) and PH with unclear multifactorial mechanisms (group 5). The diagnostics of PH are unchanged and based on right heart catheter investigations which necessitates a mean pulmonary arterial pressure of 25 mmHg or more. The most important noninvasive diagnostic examination is echocardiography, which in the case of collagen vascular disease is recommended once every year. The therapy recommendations for PAH consist of five substance classes, which are approved as single or combination therapy for treatment of PAH and inoperable CTEPH. In the non-PAH forms of PH only one medication for CTEPH is approved. The therapy of choice for CTEPH is pulmonary endarterectomy. Criteria for a PH expert center are defined in the ERS/ESC guidelines.
Find related publications in this database (Keywords): Diagnostic techniques and procedures; Chronic thromboembolic pulmonary hypertension; Cardiac catheterization; Expert center; Combined modality therapy